Related by context. All words. (Click for frequent words.) 64 Cmax 63 peak plasma concentrations 61 mL kg 61 AUC0 60 complete cytogenetic response 60 IELT 60 progression TTP 60 hours postdose 60 interquartile range 59 timepoints 59 OGTT 59 serum urate 59 PSADT 58 μmol L 58 HBeAg seroconversion 58 ug mL 58 microg 58 IU ml 58 PSA nadir 58 serum phosphorus 58 postintervention 58 virological response 58 paraprotein 58 pg mL 57 corrected QT interval 57 dose titration 57 serum concentrations 57 μg mL 57 rizatriptan 57 biochemical relapse 57 atazanavir ritonavir 57 PEG IFN 57 ml min 57 intermittent dosing 57 nM 57 serum HCV RNA 57 seroconversion 57 % Confidence Interval 57 SVR# 56 rFSH 56 alteplase 56 ml kg 56 mg/m2/day 56 plasma concentrations 56 concentration Cmax 56 lispro 56 ug kg 56 Hb A1C 56 QTcF 56 mg QD 56 alanine aminotransferase ALT 56 iPTH 56 maximal dose 56 lumbar spine BMD 56 mcg mL 56 μg ml 56 mg/m2 dose 56 mL/min/#.# m 2 56 plasma glucose levels 56 aspartate aminotransferase 55 antibody titer 55 virologic response EVR 55 #μg [001] 55 CR nPR 55 #mg QD [002] 55 serum testosterone 55 detemir 55 postop 55 radiographic progression 55 ARB telmisartan 55 serum cortisol 55 SUVmax 55 leukocyte count 55 nanomolar 55 uM 55 DAS# remission 55 mcg ml 55 GI motility 55 APTIVUS r 55 #mg dose [002] 55 extubation 55 fluticasone salmeterol 55 μg liter 55 dosing interval 55 CK MB 55 detectable HCV RNA 55 gastric acidity 55 plasma HCV RNA 55 bronchodilation 55 doxorubicin docetaxel 55 sUA 55 evaluable subjects 55 response CCyR 55 PaO 2 55 Solid Tumors criteria 55 corticosteroid dose 55 mmol kg 55 flutamide 55 EDSS score 55 octreotide LAR 54 uL 54 symptom onset 54 #μg [002] 54 intramuscularly 54 Crohn Disease Activity 54 interquartile range IQR 54 pCR 54 symptomatic intracranial hemorrhage 54 alanine aminotransferase 54 dosage regimens 54 mg kg hr 54 SpO 2 54 log# reduction 54 gastric pH 54 Partial Response 54 vasopressor 54 atheroma volume 54 timolol 54 binary restenosis 54 mcg kg 54 tobramycin inhalation solution 54 intravenous dosing 54 DLTs 54 clinically meaningful improvement 54 μg kg 54 steroid dexamethasone 54 HbA 1c levels 54 Hazard Ratio HR 54 micromolar 54 foveal thickness 54 ULN 54 Solid Tumors RECIST 54 timepoint 54 primary patency 54 CIMZIA TM 54 tumor progression TTP 54 TPV r 54 pharmacokinetic characteristics 54 angiographic restenosis 54 tipranavir r 54 postdose 54 bolus injection 54 Target Lesion Revascularization TLR 54 min -1 54 neurologic progression 54 Peg IFN 54 PASI scores 54 eosinophil count 54 CR CRu 54 beta1 54 BENICAR 54 ancrod 54 urinary N telopeptide 54 serum magnesium 54 CYT# QbG# 54 virologic response 54 piperacillin tazobactam 54 viral kinetics 53 intact parathyroid hormone 53 nmol liter 53 virologic failure 53 metabolite concentrations 53 ‰ ¥ 53 Kaplan Meier estimate 53 acetazolamide 53 diameter stenosis 53 msec 53 mL sec 53 #mg/m# [002] 53 abacavir lamivudine 53 regression coefficient 53 plasma glucose 53 myocardial reperfusion 53 serum lactate 53 creatinine ratio 53 salmeterol fluticasone propionate 53 #mg doses [002] 53 USL# 53 disease progression TTP 53 mg kg dose 53 histrelin 53 #.#mg/dL 53 mCi 53 subcutaneous infusion 53 ertapenem 53 HIV RNA 53 APTIVUS 53 oxyhemoglobin 53 HCV replicon 53 HbA 1c 53 reperfusion 53 glomerular filtration 53 urinary excretion 53 A1c levels 53 CCyR 53 salmeterol fluticasone 53 plasma pharmacokinetics 53 μg d 53 intradermal injections 53 postprandial glucose 53 mIU ml 53 ULORIC 53 serum phosphate 53 stent binary restenosis 53 p = NS 53 periprocedural 53 χ 53 dose prednisone 53 certolizumab 53 undetectable HCV RNA 53 ALT elevation 53 sustained virological response 53 adenoma recurrence 53 insulin detemir 53 serum HBV DNA 53 plasma cortisol 53 QT QTc 53 mmol l 53 expiratory flow 53 mU 53 biochemical recurrence 53 lactate dehydrogenase 53 remifentanil 53 nicardipine 53 HBV DNA levels 53 SCr 53 chlorambucil 53 serum urate levels 53 CDAI score 53 ritonavir boosted 53 creatinine clearance 53 mg m² 53 #mg/m# [001] 53 oral allopurinol 53 kg -1 53 lactate dehydrogenase LDH 53 r2 = 53 hemoglobin A1c HbA1c 53 QRS duration 53 dose proportionality 53 β blockers 53 estimated GFR 52 ipsilateral stroke 52 posttransplant 52 Fig. 2A 52 ALT elevations 52 Kaplan Meier 52 MADRS score 52 TURBT 52 Visual Analogue Scale VAS 52 achieved statistical significance 52 serum aminotransferase levels 52 Median PFS 52 HOMA IR 52 6MWD 52 subcutaneous enoxaparin 52 FSH CTP 52 mcg kg min 52 viral titers 52 #mg/day [001] 52 MBq 52 #mg/day [002] 52 AST ALT 52 Pearson correlation coefficient 52 CRp 52 NIHSS score 52 Pharmacokinetic studies 52 QTc 52 -#.# log# 52 4mg/kg 52 hematological parameters 52 antibody titers 52 mg d 52 EDSS scores 52 clodronate 52 NPH insulin 52 gemcitabine cisplatin 52 NIHSS 52 tPSA 52 liver histology 52 neutrophil counts 52 #ms [001] 52 analgesic efficacy 52 pmol L 52 chemoradiation therapy 52 preintervention 52 relapsed MM 52 sUA levels 52 recurrent VTE 52 CrCl 52 hemoglobin A1c levels 52 log# copies mL 52 posttreatment 52 glycosylated hemoglobin HbA1c 52 mmol L. 52 crossclamp 52 tirofiban 52 mg qd 52 #ug [002] 52 definite stent thrombosis 52 androgen suppression 52 renal cysts 52 #.#-#.# [011] 52 hemoglobin Hb 52 oral prednisone 52 failure MTTF 52 dose cohort 52 Fasting plasma glucose 52 isoprostane 52 glycated hemoglobin levels 52 sub maximal 52 mIU mL 52 ng dl 52 PRADAXA #mg 52 intradermal injection 52 #.#nm [002] 52 α 52 AUCs 52 IU mL 52 transaminases 52 μg dL 52 NTx 52 statistical significance p 52 laxation 52 atorvastatin #mg 52 serum TSH 52 alicaforsen enema 52 Flu Cy 52 #mg/kg [002] 52 mg kg ip 52 IOP lowering 52 GHRH 52 PDE inhibitor 52 Elitek 51 d dimer 51 LANTUS R 51 fluorescence intensity 51 CHOP chemotherapy 51 CK # plasma concentrations 51 dosing cohort 51 5-FU/LV 51 Annexin V 51 GLP1 agonist 51 #mmHg [001] 51 systemic corticosteroids 51 mg TID 51 postprocedure 51 liposomal doxorubicin 51 serum PTH 51 fluence 51 endometrial thickness 51 transgene expression 51 μg L 51 LAB GHRH 51 plasma uric acid 51 bolus dose 51 IQR 51 plasma concentration Cmax 51 serum CRP 51 randomisation 51 iodixanol 51 per deciliter mg 51 p = .# [002] 51 ng dL 51 antitrypsin 51 serum LDL cholesterol 51 #ng/ml 51 ALT normalization 51 Viral load 51 fibrinolysis 51 #OHD 51 PREZISTA ritonavir 51 virologic breakthrough 51 8mg/kg 51 pharmacokinetics PK 51 aspartate aminotransferase AST 51 #mg/dL [002] 51 activated partial thromboplastin 51 dalteparin 51 #Gy 51 desvenlafaxine succinate 51 nanomolar range 51 HbA1c levels 51 calculated creatinine clearance 51 -#.# mmol L 51 platelet reactivity 51 glycemia 51 TIMP 1 51 mCi kg 51 rHuEPO 51 milliseconds ms 51 Hematocrit 51 thyroglobulin 51 vitreous haze 51 microliters 51 MoxDuo TM IR 51 micrograms mL 51 DAPT 51 intima media thickness 51 F FDG PET 51 topical lidocaine 51 baseline LDH 51 ADAS cog 51 tumor perfusion 51 g cm 51 ug ml 51 pharmacokinetic parameters 51 transaminase levels 51 deoxy 51 racemic albuterol 51 mH 51 carotid IMT 51 tumor regressions 51 L PPDS 51 IFN α 51 mg/m2 51 #.#mL 51 postvaccination 51 serum IgG 51 IM progesterone 51 p = #.# [003] 51 mcg BID 51 TMC# r 51 intratumoral 51 #μs [001] 51 cefazolin 51 undetectable HBV DNA 51 eplerenone 51 serum ALT 51 g dl 51 P selectin 51 androgen blockade 51 Fig. 1A 51 urinary albumin excretion 50 mg orally 50 pmol 50 seropositivity 50 3mg/kg 50 partial thromboplastin 50 rFVIIa 50 mm3 50 otamixaban 50 placebo PBO 50 MVax 50 Hycamtin ® 50 comparator arm 50 parasitemia 50 ROC curves 50 Dose escalation 50 Serum creatinine 50 oral prednisolone 50 fig. S7 50 mesalamine granules 50 troponin T 50 aminotransferase elevations greater 50 intraobserver 50 lymphocyte counts 50 intratympanic 50 microgram kg 50 GnRH agonist 50 pilocarpine 50 baseline HbA1c 50 P = .# 50 death reinfarction 50 albumin excretion 50 luteal phase 50 osmolality 50 mean baseline HbA1c 50 tipranavir 50 glycated hemoglobin 50 glycosylated hemoglobin levels 50 g mL 50 XIENCE V PROMUS Stent 50 amoxicillin clavulanate 50 mmol 50 cm sec 50 daily subcutaneous injections 50 ropinirole 50 CIMZIA ™ 50 intravaginal ejaculatory latency 50 nadolol 50 antiangiogenic therapy 50 #mg BID [001] 50 IFN Beta 50 cobiprostone 50 mEq L 50 pharmacokinetic interactions 50 μl 50 dosing frequency 50 Pharmacokinetic parameters 50 #.#mg/kg [002] 50 virological failure 50 albumin excretion rate 50 budesonide foam 50 Pharmacokinetic 50 Posaconazole 50 fasting triglycerides 50 lavage 50 transaminase 50 λ 50 ispinesib administered 50 colorectal adenoma 50 CG# [003] 50 ε 50 ^ sup -1 50 circulating lymphocytes 50 CI -#.# 50 FDG uptake 50 rapid virologic response 50 Response Evaluation Criteria 50 glucuronide 50 UPDRS scores 50 doxorubicin cyclophosphamide 50 normothermic 50 FOSRENOL ® 50 conventional DMARDs 50 glycated hemoglobin HbA1c 50 bioavailable testosterone 50 prospectively defined 50 pg ml 50 pretreatment serum 50 infarct size 50 log# 50 cecal intubation 50 solubilization 50 HPV-#/# 50 serum phosphate levels 50 maximal doses 50 F FDG 50 nsec 50 sitaxsentan 50 microlitres 50 mcg QD 50 SHBG levels 50 vivo potency 50 ziprasidone 50 zonisamide SR 50 ACR# response 50 sufentanil 50 perioperatively 50 Evaluable 50 nmol 50 MS relapses 50 Fig. 3B 50 -#.# ± [002] 50 hMG 50 kVp 50 IRLS score 50 NB UVB 50 peak VO2 50 τ 50 rotigotine 50 q#d 50 selegiline 50 2ms 50 Kruskal Wallis test 50 sodium excretion 50 rebleeding 50 aminotransferase levels 50 1nm 50 cells μL 50 urate lowering therapy 50 normal ULN 50 6MW distance 50 CORE OM 50 leukotriene receptor antagonist 50 interobserver agreement 50 FFNS 50 ABC/3TC 50 Fig. 1D 50 edifoligide 49 serum sodium levels 49 Kaplan Meier estimates 49 incubations 49 electrical cardioversion 49 transthoracic 49 ìg 49 anagrelide 49 interobserver reliability 49 H2RAs 49 % CI #.#-#.# [003] 49 ischemia driven 49 ACAPODENE 49 darunavir ritonavir 49 noninferiority 49 equilibration 49 HBeAg 49 Score IPSS 49 preoperative PSA 49 graft occlusion 49 #beta estradiol 49 μSv 49 adrenoceptor 49 AUC0 #hr 49 antitumor effect 49 bezafibrate 49 fraction LVEF 49 sputum eosinophils 49 peg interferon 49 LCP AtorFen 49 oxycodone CR 49 lesional 49 liver parenchyma 49 secondary efficacy endpoint 49 Kinoid 49 serum uric acid 49 Free Survival PFS 49 serum sodium 49 acromegalic patients 49 serum lipid 49 Creatinine 49 inhaled iloprost 49 dose proportional pharmacokinetics 49 HER2 expression 49 salivary flow 49 #.#/#.# mmHg [001] 49 Ncm 49 DAS# CRP 49 Lucentis ranibizumab Genentech 49 statin monotherapy 49 serum creatinine levels 49 Scale EDSS 49 Ejection Fraction 49 hematologic toxicity 49 nondiabetic patients 49 systemically administered 49 intravenous bolus 49 Aptivus ® 49 cm H2O 49 symptomatic VTE 49 Q#IR 49 #μs [002] 49 subcutaneous dosing 49 RNA copies mL 49 HbA1C levels 49 thrombolytic therapy 49 mg XP# 49 μg m 49 cEVR 49 pretreatment baseline 49 bioavailability 49 picomolar 49 Index CDAI 49 AZT zidovudine Retrovir 49 posaconazole 49 PCWP 49 methacholine 49 β blocker 49 nodular partial response 49 alanine transaminase 49 triacylglycerols 49 serum bicarbonate 49 reinfarction 49 permanently discontinue Vectibix 49 MICARDIS 49 LDB CPR 49 baseline FEV 49 5 HT2C receptor 49 mg eq 49 serum homocysteine 49 adjuvant tamoxifen 49 biphasic 49 occluded catheters 49 pharmacodynamic PD 49 Zoledronic acid 49 estimated glomerular filtration 49 KRAS mutations occur 49 Qmax 49 ACR# responses 49 macroalbuminuria 49 serum potassium 49 severe neutropenia 49 fasting plasma glucose FPG 49 lymphocyte count 49 pulmonary arterial 49 prespecified 49 HGPIN 49 Double Blind Randomized 49 -#.# log# copies mL 49 achieved ACR# 49 CD# upregulation 49 PEGPH# 49 bendamustine 49 somatostatin analog 49 μL 49 cells mcL 49 fig. S2 49 ACR Pedi 49 pegIFN 49 flowrates 49 interobserver 49 #.#mmol L [002] 49 placebo p = 49 GH secretion 49 #mg q8h 49 tapentadol ER 49 muscarinic 49 divalproex sodium 49 1ppm 49 proteolytic cleavage 49 Platelet counts 49 atrioventricular block 49 walk distance 6MWD 49 annualized relapse 49 reintubation 49 #ppb [001] 49 sensitivity specificity 49 oral rivaroxaban 49 locoregional disease 49 evaluable patients 49 inotropic 49 hip BMD 49 #.#/#.# mm Hg [003] 49 carotid endarterectomy CEA 49 microalbuminuria 49 inecalcitol 49 intravenous IV infusion 49 cangrelor 49 rapid virological response 49 Hb A1c 49 morphometric vertebral fractures 49 mg/m2 cohort 49 RECIST criteria 49 potentiation 49 oocytes retrieved 49 AUA Symptom Score 49 hsCRP levels 49 pharmacodynamic effects 49 esophageal acid 49 mL/min/#.# m2 49 prothrombin 49 Hb levels 49 FEV1 49 glomerular filtration rate 49 aminotransferases 49 creatine kinase MB 48 prospectively stratified 48 confidence intervals CIs 48 LB# [003] 48 release cysteamine bitartrate 48 adjunctive placebo 48 treprostinil 48 mU liter 48 lumbar spine bone 48 umol L 48 antiretroviral naive 48 mmHg systolic 48 #β estradiol 48 cm -3 48 systemic toxicity 48 pT3 48 serum PSA 48 CONCERTA 48 adenotonsillectomy 48 bivalirudin monotherapy 48 methotrexate monotherapy 48 tumor resection 48 urinary albumin 48 TRUS 48 ARIKACE 48 T2 lesion volume 48 MIRAPEX 48 post prandial glucose 48 coadministration 48 HPA axis suppression 48 GnRH antagonist 48 ETDRS 48 HCCs 48 fructosamine 48 oral anticoagulation 48 tracer uptake 48 % CI #.#-#.# [007] 48 serum alkaline phosphatase 48 Doxil ® 48 oral methylnaltrexone 48 aminotransferase ALT 48 acting insulins 48 #ms [002] 48 dexamethasone Decadron 48 lopinavir r arm 48 preoperatively 48 lowest tertile 48 modified RECIST criteria 48 pomalidomide 48 PANSS scores 48 mg/# h 48 pentoxifylline 48 mediated inhibition 48 microsomal 48 absorption coefficient 48 cm ² 48 blood glucose concentrations 48 arterial elasticity 48 pegylated IFN 48 MIC# [001] 48 CSBM 48 microglial activation 48 heterozygotes 48 Capesaris 48 PSMA ADC 48 oral corticosteroids 48 lymphocytosis 48 Phase Ib study 48 Maximum Tolerated Dose 48 serum lipid levels 48 stepwise fashion 48 neutrophil count 48 telaprevir dosing 48 premixed insulin 48 calcium antagonist 48 specific antigen PSA 48 HBeAg + 48 HIV seroconversion 48 goserelin 48 cGy 48 osteoclast activity 48 hypogonadal men 48 tolterodine 48 PegIFN RBV 48 arbaclofen 48 sitosterol 48 serum calcium levels 48 mcg dose 48 T2 lesions 48 cART 48 nocturnal hypoglycaemia 48 #mg/dl 48 FOLPI 48 subscore 48 #mg #mg #mg [003] 48 ischemic lesions 48 hyperalgesia 48 moderately emetogenic 48 baseline Hb 48 intravenous tPA 48 resminostat 48 virologic responses 48 PASI score 48 virological suppression 48 locoregional recurrence 48 urinary sodium excretion 48 exhaled NO 48 adenoma detection 48 luminal diameter 48 isoproterenol 48 tertiles 48 CsA 48 airway responsiveness 48 dosage regimen 48 interferon beta 1b 48 hepatic fibrosis 48 statistical significance p = 48 mg kg IV 48 tolerated dose MTD 48 x ULN 48 MACCE 48 overt nephropathy 48 ASCT 48 excitation emission 48 HCV viral 48 methacholine challenge 48 cytoreduction 48 ug dose 48 peritumoral 48 asthma exacerbation 48 mediated dilation 48 CLARITY study 48 prolactin levels 48 hemoglobin concentrations 48 microampere 48 titers 48 oral diclofenac 48 postoperatively 48 NIH CPSI 48 chloride secretion 48 PCR amplification 48 molar ratio 48 plasma leptin 48 GP IIb IIIa 48 microvessel density 48 creatine kinase 48 systemic hypotension 48 serum phosphorous 48 selective cerebral perfusion 48 anti Xa 48 trimethoprim sulfamethoxazole 48 QRS interval 48 cystoscopic 48 mL min 48 hyperoxia 48 Insulin PH# 48 Toremifene 48 titer 48 mu g 48 Fig. 3b 48 monotonically 48 Intraocular pressure 48 paclitaxel eluting stents 48 p ≤ 48 #.#ms [001] 48 peri procedural 48 gastric emptying 48 trabedersen 48 mg tid 48 #/#mmHg 48 serum potassium levels 48 variance ANOVA 48 relapsed MCL 48 elution 48 pulmonary artery pressure 48 unfractionated heparin UFH 48 segment binary restenosis 48 attain statistical significance 48 MCyR 48 KB# [002] 48 serum albumin 48 IIIa inhibitors 48 eculizumab therapy 48 dorzolamide 48 postprandial blood glucose 48 plus medroxyprogesterone acetate 48 curve AUC 48 ZOMIG Nasal Spray 48 thyrotropin 48 ng ml 48 N telopeptide 47 μW 47 SGPT 47 APRISO 47 endoscopic remission 47 Pain Intensity 47 tumor histology 47 #.#ng/ml 47 aortic crossclamp 47 CorVue ™ 47 IFN alfa 47 serum prostate 47 Insulin sensitivity 47 Score DAS# 47 #.#g/day 47 Figure 1C 47 creatine phosphokinase 47 μg dl 47 doxazosin 47 periocular 47 dimeglumine 47 MeV 47 alkylating agent 47 degranulation 47 oncologic outcomes 47 dose atorvastatin 47 apolipoprotein B 47 intracoronary 47 pharmacodynamics PD 47 cytogenetic response 47 antiangiogenic agents 47 EURIDIS 47 premenopause 47 microbiological eradication 47 mcL 47 maximal aerobic capacity 47 SERCA2a 47 urinary cadmium 47 nadroparin 47 triacylglycerol concentrations 47 Moli# 47 dehydroepiandrosterone sulfate 47 FOLFIRI 47 tiotropium Spiriva 47 hypofractionated 47 ropivacaine 47 depolarization 47 Febrile neutropenia 47 platelet aggregation IPA 47 tissue oxygenation 47 recombinant follicle stimulating 47 genotypic resistance 47 NATRECOR ® 47 pulmonary capillary wedge 47 serum IGF 47 kcal mol 47 SIMPADICO 47 CIN3 47 plus dexamethasone 47 total thyroidectomy 47 nonnucleoside reverse transcriptase inhibitors 47 galiximab 47 isotherm 47 serum sodium concentration 47 elevated LDH 47 ultrasonographic 47 prostaglandin analogues 47 HoLEP 47 intravitreal injections 47 Index CDAI score 47 lopinavir r 47 gemcitabine carboplatin 47 gadolinium enhancing 47 Protelos R